Interestingly, combinations of HDAC1/2- and HDAC3-selective inhibitors do not reactive FXN gene expression (28), suggesting that reversal of epigenetic silencing can only be achieved by inhibition of the particular HDAC complexes residing at the FXN locus in FRDA cells. The gene discussed is HDAC3; the disease is Friedreich ataxia.